AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

AMGEN INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$424.94−7.55 (-1.75%)

Close on Oct 19, 2026

Market cap: $231.17B
P/E (TTM): 26.4
Dividend yield: 2.27%

AMGEN INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31
Revenue	36,751	33,424	28,190	26,323	25,979	25,424	23,362	23,747	22,849	22,991	21,662	20,063	18,676	17,265	15,582	15,053	14,642	15,003	14,771
Cost of Revenue	12,037	12,858	8,451	6,406	6,454	6,159	4,356	4,101	4,069	4,162	4,227	4,422	3,346	3,199	2,708	–	–	–	–
Gross Profit	24,714	20,566	19,739	19,917	19,525	19,265	19,006	19,646	18,780	18,829	17,435	15,641	15,330	14,066	12,874	–	–	–	–
Research & Development	7,272	5,964	4,784	4,434	4,819	4,207	4,116	3,737	3,562	3,840	4,070	4,297	4,083	3,380	3,167	2,894	2,864	3,030	3,266
Selling, General & Admin	7,050	7,096	6,179	5,414	5,368	5,730	5,150	5,332	4,870	5,062	4,846	4,699	5,184	4,814	4,499	3,983	3,820	3,789	3,361
Advertising Expenses	963	987	647	841	843	962	789	674	620	489	346	–	–	–	–	98	95	81	–
Total Costs & Expenses	27,671	26,166	20,293	16,757	18,340	16,285	13,688	13,484	12,876	13,197	13,192	13,872	12,809	11,688	11,270	9,508	9,136	9,789	10,791
Operating Income	9,080	7,258	7,897	9,566	7,639	9,139	9,674	10,263	9,973	9,794	8,470	6,191	5,867	5,577	4,312	5,545	5,506	5,214	3,980
Interest Expense	2,755	3,155	2,875	1,406	1,197	1,262	1,289	1,392	1,304	1,260	1,095	1,071	1,022	1,053	610	604	578	551	496
Interest & Investment Income	408	510	1,200	127	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Equity Investments	–	10	-11	-891	-33	-65	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	2,651	506	2,833	-814	259	256	753	674	928	629	603	465	420	485	448	376	276	352	309
Merger & Restructuring Charges	–	–	267	–	–	–	–	12	88	37	132	385	–	–	–	–	34	92	–
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	–	-111	87	19	178	6.00	118	21	59	404
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-780	–	-33	-288	–
Pretax Income	8,976	4,609	7,855	7,346	6,701	8,133	9,138	9,545	9,597	9,163	7,978	5,585	5,265	5,009	4,150	5,317	5,204	5,015	3,793
Income Tax Expense	1,265	519	1,138	794	808	869	1,296	1,151	7,618	1,441	1,039	427	184	664	467	690	599	963	715
Net Income	7,711	4,090	6,717	6,552	5,893	7,264	7,842	8,394	1,979	7,722	6,939	5,158	5,081	4,345	3,683	4,627	4,605	4,052	3,078
EPS (Basic)(per share)	14.33	7.62	12.56	12.18	10.34	12.40	12.96	12.70	2.71	10.32	9.15	6.80	6.75	5.61	4.07	4.82	4.53	3.79	2.76
EPS (Diluted)(per share)	14.23	7.56	12.49	12.11	10.28	12.31	12.88	12.62	2.69	10.24	9.06	6.70	6.64	5.52	4.04	4.79	4.51	3.77	2.74
Shares Outstanding (Basic, Weighted)(shares)	538	537	535	538	570	586	605	661	731	748	758	759	753	775	905	960	1,016	1,070	1,117
Shares Outstanding (Diluted, Weighted)(shares)	542	541	538	541	573	590	609	665	735	754	766	770	765	787	912	965	1,021	1,075	1,123
Dividend per Share(per share)	9.66	9.13	8.64	7.95	7.22	6.56	5.95	5.41	4.77	4.15	–	–	–	–	–	–	–	–	–
EBITDA	14,247	12,850	11,968	12,983	11,037	12,740	11,880	12,209	11,928	11,899	10,578	8,283	7,153	6,665	5,372	6,562	6,555	6,287	5,182

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 69.5%
Operating margin: 30.0%
Net margin: 23.0%
Return on equity, FY2025: 106.1%

Financial strength

Current ratio: 1.37
Debt to equity: 4.90
Debt to assets: 59.9%
Cash to current liabilities: 54.9%

Valuation

P/E ratio: 26.4
Price to sales: 6.07
Price to book: 19.78
Dividend yield: 2.27%